Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.39 Average PT from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has earned a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $13.39.

A number of analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the stock an “overweight” rating in a report on Wednesday, March 12th. Canaccord Genuity Group decreased their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, March 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th.

Insider Buying and Selling

In related news, CEO Alfred Sandrock sold 10,885 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the transaction, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. This trade represents a 2.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.39% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors have recently bought and sold shares of the business. Barclays PLC raised its position in Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after purchasing an additional 37,398 shares during the last quarter. Raymond James Financial Inc. bought a new position in Voyager Therapeutics in the 4th quarter valued at $746,000. Allspring Global Investments Holdings LLC raised its position in Voyager Therapeutics by 23.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after purchasing an additional 7,573 shares during the last quarter. Rhumbline Advisers raised its position in Voyager Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock valued at $405,000 after purchasing an additional 2,354 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Voyager Therapeutics by 8.1% in the 4th quarter. American Century Companies Inc. now owns 122,726 shares of the company’s stock valued at $696,000 after purchasing an additional 9,190 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Down 0.9%

VYGR opened at $3.40 on Friday. The firm has a market capitalization of $188.14 million, a P/E ratio of 4.79 and a beta of 0.95. The stock’s 50 day moving average price is $3.41 and its two-hundred day moving average price is $4.75. Voyager Therapeutics has a 12-month low of $2.75 and a 12-month high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. As a group, analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.